Philips shares slump on profit warning and sleep apnea device writedown

  • Philips issues second profit warning of the year
  • Says supply chain problems continue to hit sales
  • Recall leads to $1.3 bln charge on sleep care business
  • Shares drop 9% to lowest level since June ’12

AMSTERDAM, Oct 12 (Reuters) – Philips (PHG.AS) shares fell to their lowest in a decade on Wednesday as the Dutch health tech company said supply chain problems would hit sales, and wrote down 1.3 billion euros ($1.26 billion) of the value of its sleep apnea business.

Shares were down 9% at 0750 GMT at 14.13 euros, hitting their lowest level since June 2012.

In its second profit warning of the year, Philips said third-quarter core profit would drop around 60%, as ongoing supply chain problems had pushed down comparable sales by around 5%.

Philips said problems with supply shortages had been much greater than anticipated in the past months, after some signs of improvement earlier in the year, and would continue to weigh on sales in the last months of 2022.

This was expected to have limited adjusted earnings before interest, taxes and amortisation (EBITA) to 210 million euros in the third quarter, down from 512 million euros a year before.

Philips also slashed its outlook for the fourth quarter, as it now expects a “mid-single-digit” comparable sales decline while it previously guided for improvement towards the end of the year.

“This weakness will also spill into 2023 where consensus on adjusted EBITA probably also needs to come down by at least 10%,” ING analyst Marc Hesselink said in a note.

“Next step will be the 2025 targets which became very challenging especially now that the Sleep & Respiratory care business is not expected to fully recover post the recall.”


Philips last year shocked investors by recalling 5.5 million ventilators used to treat sleep apnoea, over worries that foam used in the machines could become toxic. read more read more

Outgoing Chief Executive Frans van Houten said the impairment on the sleep care business was the “best estimate” of the effects of a consent decree proposed by the U.S. Food and Drug Administration to solve the problems, which have lopped around 28 billion euros off Philips’ market value in the past 15 months.

“Details of the consent decree have not been fully negotiated at this time,” Van Houten said in a call with analysts. “It’s really early days, we can’t give much more detail today.”

Van Houten will hand over the reins of the company to newly elected CEO Roy Jakobs by the end of the week, after Philips in August had unexpectedly announced his departure.

Philips will publish its full third-quarter results on Oct. 24.

($1 = 1.0298 euros)

Register now for FREE unlimited access to

Reporting by Bart Meijer; Editing by Kim Coghill, Uttaresh.V and Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.

Read the full article here

Leave a Reply

Your email address will not be published. Required fields are marked *